Back

SENEKA: a randomized clinical trial to optimize RAASi therapy using sodium zirconium cyclosilicate in elderly patients with heart failure and chronic kidney disease at risk of hyperkalemia

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Mineralocorticoid receptor antagonists: from trials to real life Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Clara Bonanad Lozano

Research Foundation Hospital of Valencia (INCLIVA), Valencia (Spain)

6 More presentations in this session

Presentation thumbnail
Prognostic value of hyperkalemia and mineralocorticoid receptor antagonist use in heart failure: a national registry study
Doctor K. Berge (Nordbyhagen, NO)
Abstract Video
Presentation thumbnail
Temporal trends in mineralocorticoid receptor antagonist use among patients with heart failure in a community-based cohort
Doctor A. Ambrosy (San Francisco, US)
Abstract Video
Presentation thumbnail
Finerenone: from evidence to clinical practice. Data from the finerlife registry (finerenone in real life)
Mr A. Hernandez Concepcion (Palmas de Gran Canaria, Las, ES)
Abstract Video
Presentation thumbnail
Mineralocorticoid receptor antagonists in heart failure: real-world uptake, dose titration, hyperkalaemia trends, and potassium binder use
Doctor T. Furlan (Trbovlje, SI)
Abstract Video
Presentation thumbnail
Real-life indications of finerenone in patients with heart failure with mildly reduced or preserved ejection fraction
Doctor G. Antonelli (Rozzano, IT)
Abstract Video

Access the full session

Session thumbnail
Mineralocorticoid receptor antagonists: from trials to real life

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Design and baseline characteristics of REALIZE K: a placebo-controlled randomized-withdrawal trial of sodium zirconium cyclosilicate for hyperkalaemia management in patients with HF and reduced EF
thumbnail
Congress Presentation
Sodium zirconium cyclosilicate for the management of hyperkalaemia in patients with heart failure with reduced ejection fraction - the REALIZE-K open-label run-in phase
thumbnail
Congress Session
Late breaking clinical trials: medical therapy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources